Amendment No. 1 to the Territory B Alliance Support AgreementTerritory B Alliance Support Agreement • August 17th, 2009 • Bristol Myers Squibb Co • Pharmaceutical preparations
This AMENDMENT No. 1 (this “Amendment No. 1”), dated as of October 17, 2001 and effective as of October 1, 2001 (the “Effective Date”) to the Territory B Alliance Support Agreement dated as of January 1, 1997 is hereby made by and between Sanofi-Synthélabo, a société anonyme organized and existing under the laws of the French Republic (“SSBO”) as the successor in interest to Sanofi, a société anonyme organized under the laws of the French Republic, and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and, together with SSBO, the “Parties” and, individually, each a “Party”).
Confidential Treatment Requested AMENDMENT NO. 4 TO THE TERRITORY B ALLIANCE SUPPORT AGREEMENTTerritory B Alliance Support Agreement • February 15th, 2013 • Bristol Myers Squibb Co • Pharmaceutical preparations
This Amendment No. 4 (this “Amendment No. 4”), dated as of January 1, 2013 (the “Effective Date”) to the Territory B Alliance Support Agreement (“JVB Support Agreement”), dated as of January 1, 1997, as amended by that certain Amendment No. 1, dated October 17, 2001 (“Amendment No. 1”), that certain Amendment, dated October 2, 2007 (“Amendment No. 2”) and that certain Amendment No. 3, dated April 10, 2012 (“Amendment No. 3”) is hereby made by and between Sanofi, a French société anonyme (“Sanofi”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and together with Sanofi, the “Parties” and, individually, each a “Party”). Except as otherwise noted, any capitalized terms not herein defined shall have the meaning ascribed to them in the JVB Support Agreement.
